CLINICAL CORNER: Spectranetics’ DCB, Pixium’s Bionic Vision, Endologix EVAS, Biocartis’ Liquid Biopsy
This article was originally published in Clinica
You may also be interested in...
The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.
TCT Round-Up: The Next Generation Of Drug-Eluting Stents, Drug-Coated Balloon Featured At Washington Conference
One of the world’s largest showcases for new interventional cardiology technology, the 2016 Transcatheter Cardiovascular Therapeutics (TCT) 2016 scientific sessions, were held Oct. 29-Nov. 2 in Washington, DC. This year’s edition of TCT featured many presentations on new drug-eluting coronary stent technologies, as well as drug-coated balloons for peripheral interventions.
Competition in the retinal implant market heats up as Pixium CE marks its second-generation bionic vision system, designed to offer key advantages including higher resolution and explantability.